新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 政策 » “长安居,大不易”生物医药产业汇聚波士顿或致一屋难求!

“长安居,大不易”生物医药产业汇聚波士顿或致一屋难求!

来源:生物谷 2014-11-28 14:12

2014年11月28日讯 /生物谷BIOON/ --如果让生物医药产业界人士列举出目前世界上三个最著名的生物医药中心,那么美国波士顿绝对会榜上有名。

作为美国生物医药界的圣地,波士顿这里汇聚了麻省理工、哈佛等全球最顶尖的学术机构,为生物医药企业产业成果转化提供了源源不绝的动力。 同时马萨诸塞州的政策倾斜也使得这一地区对各大生物医药企业平添了几分吸引力。

然而,正是世界各大医药巨头都纷纷看中波士顿,也使得这一产业中心却多了几分幸福的"烦恼"。根据美国相关地产机构的统计,由于各大生物医药公司纷纷进驻这一地区,波士顿地区的生物研发实验室用地储备已经降至近十年来的最低值--13.9%。而且这还是将沃特敦、列克星敦市、沃尔瑟姆等周边地区都计算在内的结果。单纯波士顿地区的实验室用地储备则仅为8.5%左右。而1998年-2011年这一数字则为17.3%。

最近进驻波士顿的一家生物医药公司为百特医疗,公司承租了坎布里奇市一处20万平方英尺的实验室用地,以保证自己能够与MIT、哈佛等学术机构能够畅通交流。而辉瑞、诺华、赛诺菲等生物医药巨头也都纷纷准备扩大公司在该地区研究机构的规模。分布在波士顿郊区的一些生物医药公司也增加了在该地区的投入和人员配比。

这一趋势或许在某些人看来是生物医药产业在该地区持续走红的标志之一。但是另外一些分析人士则指出,相关部门和生物医药公司应当察觉这里隐含的风险。在如此多的扩建计划中是否会存在着盲目跟风的现象?如此多的大型生物医药公司挤占该地区的资源是否会阻碍中小型生物医药公司的发展进而不利于整个生物医药产业的发展?如果无法消除这一隐患,或许波士顿地区在未来的某一天可能会迎来生物医药产业泡沫的破碎,重创美国,乃至世界生物医药产业。(生物谷Bioon.com)

详细英文报道:

The growing biotech hub in the Boston area has attracted drug developers virtual and multinational to set up shop near the bay, but the boom in demand is threatening to outstrip inventory, according to the Boston Business Journal.

Per real estate firm Transwestern's latest look at the market, the vacancy rate for lab space in Cambridge is at a roughly 10-year low of 13.9%, BBJ reports. And stretching out to the suburbs--including Watertown, Lexington and Waltham--the availability rate hovers around 8.5%. By comparison, from 1998 to 2011, suburban lab vacancy averaged about 17.3%, according to Transwestern, reflecting the region's explosive life sciences growth.

The area's latest major tenant is Baxter ($BAX), which, on the eve of spinning out its biopharma division, leased a 200,000-square-foot operation in Cambridge's Kendall Square, setting it up right next to MIT, Harvard and a slew of startups. The allure of working shoulder-to-shoulder with top academics and forward-thinking biotechs has lured Pfizer ($PFE), Novartis ($NVS) and Sanofi ($SNY) to expand their presences in the neighborhood, and Johnson & Johnson ($JNJ) has stood up one of its deal-scouting startup factories in Cambridge.

And suburban demand remains high, as well, with Shire ($SHPG) building up a U.S. headquarters in Lexington, announcing this month plans to transfer 500 workers to a home base that will employ roughly 2,000. AstraZeneca ($AZN) has been expanding its presence in the suburbs this year, as have smaller outfits likeKala Pharmaceuticals, Verastem and ImmunoGen.

The resulting strains on supply have had downstream effects on firms looking to follow the trend, Transwestern Partner Eric Smith told BBJ, and the firm has "seen some companies hit the pause button on their expansion plans."

But more inventory is on the way. Alexandria Real Estate has just opened a 408,000-square-foot lab space in Cambridge with Biogn Idec ($BIIB) as an anchor tenant, and, working with National Development, is nearing a ribbon-cutting for a 413,000-square-foot Boston hub.

 

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库